MiRNA marker in serum exosome related to early diagnosis of lung adenocarcinoma and application

Abstract

The invention discloses a miRNA marker in a serum exosome related to early diagnosis of lung adenocarcinoma and application. The marker is selected from hsa-miR-4516, hsa-miR-342-3p, hsa-miR-199a-3p, hsa-miR-150-5p, hsa-miR-140-3p, hsa-miR-18a-5p, hsa-miR-222-3p, hsa-miR-27a-3p, hsa-miR-29a-3p, hsa-miR-221-3p, hsa-miR-500a-3p, hsa-miR-6126 and hsa-miR-6715a-3p. The marker can effectively separate early lung adenocarcinoma cases from healthy people. The marker and probes thereof can be used for preparing a lung adenocarcinoma early diagnosis kit. The marker has an assisting effect on early diagnosis of lung adenocarcinoma.

Description

technical field [0001] The invention belongs to the field of biotechnology and diagnostics, in particular to a serum exosome miRNA marker for early diagnosis of lung adenocarcinoma and its application. Background technique [0002] Lung cancer diagnosis lacks early diagnostic methods and specific biomarkers [0003] Lung cancer is the second most common cancer worldwide (prostate cancer with the highest incidence in men; breast cancer with the highest incidence in women). More than 1.2 million people die from lung cancer every year in the world, accounting for about 28% of the global death toll. Although some molecular targeted therapies currently used in the diagnosis and treatment of lung cancer are quite effective, the five-year survival rate of patients is still not optimistic. The reason is that there is a lack of early diagnostic methods and diagnostic molecular markers, and most lung cancer patients are already at an advanced stage when they are diagnosed. [0004]...

AI Technical Summary

Problems solved by technology

However, these serological markers are broad-spectrum cancer diagnostic molecular markers, and their role in the specific diagnosis and early diagnosis of lung cancer has great limitations.

Images